Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Heavy metal or compound thereof
Reexamination Certificate
2005-04-05
2005-04-05
Pak, John (Department: 1616)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Heavy metal or compound thereof
C424S422000, C424S620000, C424S629000, C424S649000, C424S184100, C424S277100, C514S002600, C514S008100, C514S012200, C514S021800, C514S023000, C514S025000, C514S028000, C514S029000, C514S031000, C514S034000, C514S045000, C514S049000, C514S090000, C514S110000, C514S171000, C514S183000, C514S184000, C514S185000, C514S249000, C514S274000, C514S283000, C514S444000, C514S449000, C514S492000, C514S504000, C514S588000, C514S615000, C514S733000, C514S908000
Reexamination Certificate
active
06875451
ABSTRACT:
The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
REFERENCES:
patent: 132275 (1872-10-01), Gettings
patent: 232807 (1880-10-01), Dennett
patent: 3700498 (1972-10-01), Kanazawa et al.
patent: 4497780 (1985-02-01), Barin et al.
patent: 5759837 (1998-06-01), Kuhajda et al.
patent: 1061908 (1992-06-01), None
patent: 1079391 (1993-12-01), None
patent: 1081104 (1994-01-01), None
patent: 1119113 (1996-03-01), None
patent: 1121807 (1996-05-01), None
patent: 1122700 (1996-05-01), None
patent: 1131037 (1996-09-01), None
patent: 1133725 (1996-10-01), None
patent: 51-88620 (1976-03-01), None
patent: WO 9402108 (1994-02-01), None
patent: WO 9501789 (1995-01-01), None
patent: WO 9522336 (1995-08-01), None
Rosner, S., “Immunological enhancement of chemotherapy in advanced brain cancer,” Acta Neurologica Latinoamericana, vol. 21(1-4), pp. 126-132 (1975).*
Repetto, G. et al., “Comparatice in vitro effects of sodium arsenite and sodium arsenate on neuroblastoma cells,” Toxicology, vol. 92(1-3), pp. 143-153 (1994).*
Shimotsuura, S., “Studies on the antineoplasmic actions of As2O3,” Shikwa Gakuho, vol. 86, pp. 1237-1253, 1986.*
Shen, Zhi-Xiang et al., “Use of arsenic trioxide (As2O3) in the treatment of Acute Promyelocytic Leukemia . . . ” Blood, vol. 89(9), pp. 3354-3360, May 1997.*
Chen, Guo-Qiang et al., “In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of Acute Promyelocytic leukemia . . . ” Blood, vol. 88(3), pp. 1052-1061, Aug. 1996.*
Zhu, Jun et al., “Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia,” Proc. Natl. Acad. Sci., vol. 94, pp. 3978-3983, Apr. 1997.*
Sun, Hongde et al., “32 cases of acute early granulocytic leukemia treated with Al-Ling No. 1 in combination with Chinese medical practice of pattern identification,” Zhongguo Zhongxiyi Jiehe Zazhi, vol. 12(3), pp. 170-171, 1992.*
Peng, Zhang et al., “Treatment of acute promyelocytic leukemia with intravenous arsenic trioxide,” Chinese Journal of Hematology, vol. 17, Translation, Feb. 1996.*
International Search Report (Jul. 2004).
Kunio Kitamura et al., “New Retinoids and arsenic compounds for the treatment of refractory acute promyelocylic leukemia: clinical and basic studies for the next generation”, Cancer Chemother Pharmacol, (1977), 40 (Suppl) pp. S36-S41.
Zhu Chen et al., “Acute Promyelocytic Leukemia: Cellular and Molecular Basis of Differentiation and Apoptosis”, Pharmacol. Ther., vol. 76, Nos. 1-3, pp. 141-149, 1997.
Database Medline Online! US National Library of Medicine (NLM), Bethesday, MD US; Aug. 25, 1997, Melino G. et al., “Retinoic acid receptors alpha and gamma mediate the induction of “tissue” transglutaminase activity and apoptosis in human neuroblastoma cells”, XP002284763, Database accession No. NLM9281352 *ABSTRACT.
Database Medline Online! US National Library of Medicine (NLM) Bethesda, MD, US; Jul. 1997, Cooper M. P. et al., “All-trans retinoic acid induced gene expression and growth inhibition in head and neck cancer cell lines” XP002284764 Database accession No. NLM9307717 *ABSTRACT & Oral Oncology, Jul. 1997, vol. 33, No. 4, pp. 270-274, ISSN: 1368-8375.
International Search Report for EP 03019594 (Nov. 4, 2003).
Matthew Block et al., “Biological Studies with Arsenic IV. The Histopathiologic Effect of Arsenic Upon the Hematopoietic Tissues of Patients with Leukemia”, The Journal of Laboratory and Clinical Medicine, vol. 41, No. 4, Apr. 1953, pp. 499-515.
P. Rousellot et al., “Arsenic derivatives: Old drugs for new indications!, Les Derives Arsenicaux: De Vieux Medicaments Pour Des Indications Renouvelees”,Hematologie, vol. 4, No. 3, May 1998, pp. 95-97.
P. Rousellot et al., “Arsenic trioxide (AS2O3) and Metarsoprol induce myeloma cell apoptosis in vitro with a preferential effect on tumoral cells in patients' bone marrow”, Blood, vol. 90, No. 10, Nov. 15, 1997, p. 325A.
Z. Xie et al., “Metasoprol and arsenic trioxide increase cell death on doxorubicin-resistant human leukemia and myeloma cells by regulating expression of BCL-2 apoptosis regulatory family”, BLOOD, vol. 90, No. 10, Nov. 15, 1997, pp. 495 A.
DATABASE EPODOC 'Online! European Patent Office, the Hauge, NL., CN1180563, May 16, 1998, Zhao Qingtuan: XP002260136 *abstract*.
International Search Report for EP 03019595 (Oct. 24, 2003).
Edward B. Silberstein, “Radionuclide Therapy of Hematologic Disorders”, Seminars in Nuclear Medicine, vol. 9, No. 2, Apr. 1979, pp. 100-107.
David A. Sears MD, “History of the Treatment of Chronic Myelocytic Leukemia”, American Journal of the Medical Sciences, vol. 296, No. 2, Aug. 1988, pp. 85-86.
Zhi-Xiang Shen et al., “Use of Arsenic Trioxide (As2O3) in the Treatment of Acute Promyelocytic Leukemia (APL); II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients”, Blood, vol. 89, No. 9, May 1997, pp. 3354-3360.
International Search Report for EP Application No. 03019628 (Oct. 27, 2003).
W. Zhang et al., “The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms”, Leukemia (1998), vol. 12, No. 9, Sep. 1998, pp. 1383-1391.
John G. Kidd, “Effects of Arsenic Azoproteins on Mouse Lymphoma Cells in Vivo* With Observations on the Effects of Other “Anti-Lymphoma” Agents and On the Susceptibility to these Effects of Lymphoma Cells of Various Types”, Journal of Experimental Medicine, vol. 108, 1958, pp. 665-684.
Jacques Debray, “Treatment of Hodgkin's Disease”, Therapie, vol. 9, 1954, pp. 106-118.
G. Lotti, “Abandonment of arsenic in medical therapy of malignant granuloma (Hodgkin's disease): is it justified?!” Revue Medicale Du Moyen-Orient, vol. 24, No. 2, Mar. 1967 pp. 110-111.
International Search Report for EP 03029713 (Mar. 31, 2004).
D.A. Sears, “History of the Treatment of Chronic Myelocytic Leukemia”, American Journal of Medical Sciences, vol. 296, No. 2, Aug. 1988, pp. 85-86.
Y.L. Kwong et al., “Delicious Poison: Arsenic Trioxide for the Treatment of Leukemia”, Blood, vol. 89, No. 9, May 1997, pp. 3487-3488.
Sun et al., “Ai Ling #1 and Traditional Chinese Medicine in the Treatment of 32 Patients with Acute Promyelocytic Leukemia,” Chinese J of Traditional Chinese and Western Medicine, pp. 170-171, vol. 12, No. 3, 1992.
“Arsen (III)-Sulfid As2S2”, Gmelin's Arsenic, 8th. Edition, 17: 422-433, 1952.
“Goodman & Gilman's The pharmacological basis of therapeutics”, ninth edition, McGraw-Hill, Health Professions Division, pp. 1659-1662 (Date not Known).
“Inorganic Arsenic Compounds Other Than Arsine Health and Safety Guide, Health and Safety Guide No. 70”, WHO, Geneva, 1992.
Akao et al., “Arsenic Induces Apoptosis in B-cell Leukemic Cell Lines in Vitro: Activation of Caspases and Down-regulation of Bcl-2 Protein”, British J of Hematology, 102. 1055-1060, 1998.
Andre et al., “The PML and PML/RARα Domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic”, Experimental Cell Research, 229: 253-260, 1996.
Arsenic, Environmental Health Criteria 18, Geneva: WHO, 1981.
Chemical Abstract, 63-Pharmaceuti
Ellison Ralph M.
Mermelstein Fred H.
Pak John
PolaRx Biopharmaceuticals Inc.
LandOfFree
Compositions and methods for the treatment of primary and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the treatment of primary and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the treatment of primary and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3395900